SEC Tracker
Get the app

Kalobios Pharmaceuticals

KaloBios Receives $5.5M in New Financing From Existing Investors

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
Exhibit 10.3
Material contract
Exhibit 10.4
Material contract
Exhibit 10.5
Material contract
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Takes on a new financial obligation (2.03)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Kalobios Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.